Onset or exacerbation of cutaneous psoriasis during TNFα antagonist therapy

Wendling, Daniel; Balblanc, Jean-Charles; Briançon, D.; A, Brousse; Lohse, Anne; Deprez, Philippe; Humbert, Philippe; Aubin, F.

doi:10.1016/j.jbspin.2007.06.011

Cited by 57 publications

(38 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Psoriasis, or a psoriasiform dermatitis, may appear de novo or as flare following treatment in patients with a previous diagnosis of psoriasis, and sterile palmoplantar pustulosis is also frequently reported. This may be associated with nail changes, pustular folliculitis, alopecia and changes in the morphology of psoriasis vulgaris [2,3]. Treatment of these instances of paradoxical psoriasis often requires withdrawal of the drug and switching to another anti-TNF agent, which may lead to recurrence or persistence of the rash and loss of the therapeutic effect on the underlying condition.…”

Section: Introductionmentioning

confidence: 99%

Ustekinumab Treatment of TNF Antagonist-Induced Paradoxical Psoriasis Flare in a Patient with Psoriatic Arthritis: Case Report and Review

Puig¹,

Morales-Múnera²,

López‐Ferrer³

et al. 2012

Dermatology

View full text Add to dashboard Cite

Background: Therapy with tumour necrosis factor α (TNF) inhibitors can be associated with paradoxical reactions, namely the de novo development or flaring of conditions that usually respond to these therapeutic agents, such as arthritis, inflammatory bowel disease, sarcoidosis or psoriasis. They are considered a class effect of these drugs, and their incidence ranges from 1 to 5%, with paradoxical psoriasis (psoriasis vulgaris, palmoplantar pustulosis, scalp psoriasis and their combinations) being most frequently reported. Treatment of paradoxical psoriasis often requires withdrawal of the inducing drug and switching to another anti-TNF agent, but often this cannot avoid recurrence or persistence of the rash and/or loss of the therapeutic effect on the underlying condition. Case Report: We report on a 47-year-old woman who developed incapacitating palmoplantar pustulosis and psoriasis vulgaris flare with severe scalp and nail involvement after 5 months of treatment with adalimumab for psoriatic arthritis. Several treatments, including topical corticosteroids, photochemotherapy, ciclosporin, acitretin and etanercept 50 mg twice a day for 1 month, were ineffective or not tolerated. Treatment with ustekinumab 45 mg provided complete resolution of skin lesions with acceptable therapeutic control of the arthritis, with a follow-up duration of 16 months. Conclusion: A review of the reported cases suggests that this may be a therapeutic option in patients who develop paradoxical psoriasis while under treatment for arthritis or Crohn’s disease.

show abstract

Section: Introductionmentioning

confidence: 99%

Ustekinumab Treatment of TNF Antagonist-Induced Paradoxical Psoriasis Flare in a Patient with Psoriatic Arthritis: Case Report and Review

Puig¹,

Morales-Múnera²,

López‐Ferrer³

et al. 2012

Dermatology

View full text Add to dashboard Cite

show abstract

“…This kind of new onset or reactivation of psoriasis under biologic therapy for rheumatologic indications has been reported with TNF blockers 7 , rituximab 8 , and abatacept 9 .…”

Section: To the Editormentioning

confidence: 80%

Psoriasis Onset with Tocilizumab Treatment for Rheumatoid Arthritis: Figure 1.

Wendling¹,

Letho-Gyselinck²,

Guillot³

et al. 2012

J Rheumatol

Self Cite

View full text Add to dashboard Cite

“…There has been a recent observational report showing the utility of GOL in SpA associated with refractory uveitis [Miserocchi et al 2014]. Although TNF-α inhibitors are effective in the treatment of skin and nail lesions of psoriasis, about 5% of patients may develop an onset or exacerbation of psoriasis during treatment [Kary et al 2006;Wendling et al 2008]. TNF-α inhibitors showed quite different effects on the bowel.…”

Section: Biological Therapiesmentioning

confidence: 99%

Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies

Caso

Costa

Puente

et al. 2015

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Spondyloarthritis represents a heterogeneous group of articular inflammatory diseases that share common genetic, clinical and radiological features. The therapy target of spondyloarthritis relies mainly in improving patients' quality of life, controlling articular inflammation, preventing the structural joints damage and preserving the functional abilities, autonomy and social participation of patients. Among these, traditional disease-modifying antirheumatic drugs have been demonstrated to be effective in the management of peripheral arthritis; moreover, in the last decade, biological therapies have improved the approach to spondyloarthritis. In patients with axial spondyloarthritis, tumor necrosis factor α inhibitors are currently the only effective therapy in patients for whom conventional therapy with nonsteroidal anti-inflammatory drugs has failed. The aim of this review is to summarize the current experience and evidence about the pharmacological approach in spondyloarthritis patients.

show abstract

Onset or exacerbation of cutaneous psoriasis during TNFα antagonist therapy

Cited by 57 publications

References 10 publications

Ustekinumab Treatment of TNF Antagonist-Induced Paradoxical Psoriasis Flare in a Patient with Psoriatic Arthritis: Case Report and Review

Ustekinumab Treatment of TNF Antagonist-Induced Paradoxical Psoriasis Flare in a Patient with Psoriatic Arthritis: Case Report and Review

Psoriasis Onset with Tocilizumab Treatment for Rheumatoid Arthritis: Figure 1.

Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies

Contact Info

Product

Resources

About